TFR Capital LLC. Buys Shares of 2,162 Johnson & Johnson (NYSE:JNJ)

TFR Capital LLC. purchased a new position in Johnson & Johnson (NYSE:JNJ - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 2,162 shares of the company's stock, valued at approximately $313,000.

A number of other hedge funds have also recently modified their holdings of the company. Copley Financial Group Inc. raised its holdings in shares of Johnson & Johnson by 3.5% during the fourth quarter. Copley Financial Group Inc. now owns 4,320 shares of the company's stock valued at $625,000 after acquiring an additional 146 shares in the last quarter. Dogwood Wealth Management LLC increased its position in Johnson & Johnson by 13.9% during the 4th quarter. Dogwood Wealth Management LLC now owns 4,224 shares of the company's stock valued at $611,000 after purchasing an additional 514 shares during the period. American Investment Services Inc. bought a new position in Johnson & Johnson in the 4th quarter worth $1,462,000. BridgePort Financial Solutions LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth about $412,000. Finally, Park Square Financial Group LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $331,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Down 0.5%

NYSE JNJ traded down $0.72 during mid-day trading on Wednesday, reaching $152.53. The stock had a trading volume of 8,423,290 shares, compared to its average volume of 7,953,086. The stock has a market cap of $367.00 billion, a PE ratio of 22.94, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company has a fifty day moving average price of $154.85 and a 200 day moving average price of $153.65.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.41%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Wall Street Analyst Weigh In

Several analysts have commented on JNJ shares. Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd. Bank of America lowered their target price on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Barclays lowered their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Finally, Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Eleven analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.